ASCO 2023 | The benefits of fecal transplantation in treating immunotherapy-induced colitis

Yinghong Wang, MD, PhD, from The University of Texas MD Anderson Cancer Center, highlights the compelling advantages of fecal transplantation in treating immunotherapy-induced colitis. These benefits encompass neutrality, safety, effectiveness, rapid action, and minimal to no immunosuppressive impact. This aligns with the desired attributes for future colitis treatment in cancer patients undergoing immunotherapy, as it avoids potential counteractive interactions that immunosuppression might pose to cancer treatment outcomes. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.